Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) has announced that its subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd. (referred to as "GeneScience Pharmaceuticals"), recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The domestic production drug registration clinical trial application for GeneScience Pharmaceuticals' GenSci155 Injection has been approved.
The drug is intended for the prevention of bronchopulmonary dysplasia (BPD) in premature infants and the treatment of primary insulin-like growth factor-1 deficiency (PIGFD), with subcutaneous injection as the route of administration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.